Johnson & Johnson's Cilta-Cel Receives European Commission Approval for Multiple Myeloma Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission approval for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) to treat adult patients with relapsed and refractory multiple myeloma who have received prior therapy, including lenalidomide, and have shown disease progression. Cilta-cel is the first BCMA CAR-T therapy approved in Europe for eligible patients as early as first relapse. This decision follows positive results from the Phase 3 CARTITUDE-4 study, demonstrating its efficacy and safety in patients with relapsed and lenalidomide-refractory multiple myeloma.